Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q2 2025
Arcturus Therapeutics Holdings (ARCT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Arcturus Therapeutics Holdings (ARCT) reported revenue of $28.3M for the second quarter 2025 (Q2 2025), -43% from a year earlier and -4% from the quarter before. Operating margin was -41.0%, net loss $9.2M (32.4% of revenue).
Arcturus Therapeutics Holdings, Q2 2025: revenue $28.3M (-43% year over year), operating margin -41.0%, net loss $9.2M, operating cash flow −$5.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $28.3M | -4% | -43% |
| Operating profit | −$11.6M | — | — |
| Net earnings | −$9.2M | — | — |
| Operating cash flow | −$5.8M | — | — |
What changed
Revenue was $28.3M in Q2 2025, down 43% year over year and down 4% from the previous quarter. Collaboration Revenue was the largest line at 87% of revenue. Collaboration Revenue lost $21.5M year over year (down 47%), 100% of the total change.
Operating costs exceeded revenue by $11.6M, an operating margin of -41.0%. Total costs fell 44% while revenue fell 43%. The quarter ended with a net loss of $9.2M, narrower than the previous quarter's $14.1M loss. Non-operating items added $2.4M, -27% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$5.8M. Non-cash charges added back $800K of depreciation and amortization and $6.2M of share-based compensation. Working capital and other items used $3.6M.
Questions
What was Arcturus Therapeutics Holdings' revenue in the second quarter 2025?
Arcturus Therapeutics Holdings (ARCT) reported revenue of $28.3M for the second quarter 2025 (Q2 2025), -43% from a year earlier and -4% from the quarter before.
Was Arcturus Therapeutics Holdings profitable in the second quarter 2025?
Operating loss was $11.6M (-41.0% of revenue) and net loss $9.2M.